AAV Mediated Expression of Mouse IL-12 Shows Potent Anti-Tumor Activity and Immune Response Alone and in Combination with Anti-PD1 in Syngeneic Murine Tumor Models

被引：0
|
作者：
Sutton, David [1 ]
Prentiss, Pilar [1 ]
Furmanski, Brian [1 ]
机构：
[1] Kriya Therapeut, Translat Dev, Redwood City, CA USA
来源：
MOLECULAR THERAPY | 2022年 / 30卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
337
引用
收藏
页码：161 / 161
页数：1
相关论文
共 50 条
  • [41] Poly (I:C) enhances the anti-tumor activity of canine parvovirus NS1 protein by inducing a potent anti-tumor immune response
    Gupta, Shishir Kumar
    Yadav, Pavan Kumar
    Tiwari, A. K.
    Gandham, Ravi Kumar
    Sahoo, A. P.
    TUMOR BIOLOGY, 2016, 37 (09) : 12089 - 12102
  • [42] Tumor suppressor TUSC2 immunogene therapy is synergistic with anti-PD1 in lung cancer syngeneic mouse models
    Meraz, Ismail M.
    Majidi, Mourad
    Shao, RuPing
    Feng, Meng
    Cao, Xiaobo
    Rice, David
    Sepesi, Boris
    Ji, Lin
    Roth, Jack
    CANCER RESEARCH, 2017, 77
  • [43] Anti-tumor activity of GM-CSF and IL-12 expressing oncolytic HSV-1
    Kim, J. H.
    Moon, D. H.
    Kim, K. J.
    Yoo, Y. E.
    Choi, K. J.
    HUMAN GENE THERAPY, 2018, 29 (12) : A161 - A161
  • [44] Synergistic Anti-Tumor Efficacy Achieved by Reversing Drug Resistance through the Regulation of the Tumor Immune Microenvironment with IL-12 and Osimertinib Combination Therapy
    Ding, Huiqin
    Wu, Lijuan
    Qin, Huan
    Fu, Wenhui
    Wang, Yajun
    Wu, Mingyuan
    Wang, Jiangang
    Han, Yantao
    JOURNAL OF CANCER, 2024, 15 (14): : 4534 - 4550
  • [45] PERK INHIBITOR HC-5404 DEMONSTRATES IMMUNEACTIVATION AND ANTI-TUMOR EFFICACY IN COMBINATION WITH ANTI-PD1 IMMUNE CHECKPOINT INHIBITOR ANTIBODY
    Chan, Anissa S. H.
    Drees, Jeremy
    Li, Yunfang
    Kangas, Takashi
    Zhang, Weiyu
    Fumagalli, Maria
    Dewji, Iman
    Qiu, Xiaohong
    Collette, Nick
    Harrison, Ben
    LaCayo, Ashley
    Vidal, Veronica Calvo
    Dudgeon, Crissy
    Stokes, Michael
    Lightcap, Eric
    Surguladze, David
    Bose, Nandita
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A921 - A921
  • [46] Neuritin-specific antibody impedes the Treg-mediated suppression of anti-tumor immunity and enhances response to anti-PD1
    Zhang, Kaimin
    Zhao, Taowen
    Riaz, Fraooq
    Li, Yikui
    Wei, Ping
    Fang, Xiang
    Zhou, Zhiyi
    Kou, Wei
    Pan, Fan
    MOLECULAR IMMUNOLOGY, 2025, 181 : 148 - 159
  • [47] Recombination plasmid carrying hcg and survivin combination IL-12 generates specific immune responses and anti-tumor effects in a murine breast carcinoma model
    Wang, Lei
    Liu, Ying
    Huo, Jingrui
    Liu, Yuanyuan
    Tian, Yi
    Yang, Xiaohui
    Zhang, Jingjing
    Liu, Yingfu
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (07): : 10676 - 10682
  • [48] Evaluating anti-tumor activity of the human anti-PD-1 antibody pembrolizumab using humanized mouse models
    Linn, Douglas E.
    Cristescu, Razvan
    Ray, Kallol
    Zhang, Shuli
    Dhandapani, Sripriya
    Kaliyaperumal, Sarav
    Yearley, Jennifer H.
    Long, Brian J.
    CANCER RESEARCH, 2017, 77
  • [49] Combination of ANTI-PD-1/ANTI-PD-L1 Antibodies With the Distinct Character Exerts Preferable Anti-Tumor Immune Cycle in a Murine Neuroblastoma Model
    Inoue, S.
    Horiuchi, Y.
    Setoyama, Y.
    Takeuchi, Y.
    Murakami, T.
    Odaka, A.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S157 - S157
  • [50] Evaluation of the antitumor activity and molecular characterization of mouse syngeneic tumor models in response to anti-PD-1 treatment as a single agent and in combination with approved agents
    Hirsch, Heather
    Mangadu, Ruban
    Cai, Mingmei
    Ma, Yanhong
    Phan, Uyen
    Wang, Yaolin
    Sriram, Venkataraman
    Phillips, Joseph H.
    McClanahan, Terri
    Long, Brian
    Pinheiro, Elaine M.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
12345